{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:32:58Z","timestamp":1792740778932,"version":"4.5.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"21","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1084951"],"award-info":[{"award-number":["1084951"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.vaccine.2019.04.020","type":"journal-article","created":{"date-parts":[[2019,4,13]],"date-time":"2019-04-13T01:16:48Z","timestamp":1555118208000},"page":"2768-2782","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":206,"title":["Case fatality rates of invasive meningococcal disease by serogroup and age: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"37","author":[{"given":"Bing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Santoreneos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Haji Ali Afzali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.vaccine.2019.04.020_b0005","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","article-title":"Meningococcal carriage by age: a systematic review and meta-analysis","volume":"10","author":"Christensen","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2019.04.020_b0010","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jinf.2016.07.016","article-title":"Clinical diagnoses and outcomes of 4,619 hospitalised cases of laboratory-confirmed invasive meningococcal disease in England: linkage analysis of multiple national databases","volume":"73","author":"Edge","year":"2016","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2019.04.020_b0015","unstructured":"European Centre for Disease Prevention and Control. Annual Epidemiological Report 2016 \u2013 Invasive meningococcal disease (2014 data). <https:\/\/ecdc.europa.eu\/en\/publications-data\/invasive-meningococcal-disease-annual-epidemiological-report-2016-2014-data> (accessed 25 July 2017)."},{"issue":"8","key":"10.1016\/j.vaccine.2019.04.020_b0020","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1093\/cid\/cix993","article-title":"Current epidemiology and trends in meningococcal disease-United States, 1996\u20132015","volume":"66","author":"MacNeil","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2019.04.020_b0025","doi-asserted-by":"crossref","first-page":"E454","DOI":"10.33321\/cdi.2016.40.50","article-title":"Rise in invasive serogroup W meningococcal disease in Australia 2013\u20132015","volume":"40","author":"Martin","year":"2016","journal-title":"Commun Dis Intell Q Rep"},{"issue":"16","key":"10.1016\/j.vaccine.2019.04.020_b0030","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/j.vaccine.2017.03.007","article-title":"The epidemiology of invasive meningococcal disease in EU\/EEA countries, 2004\u20132014","volume":"35","author":"Whittaker","year":"2017","journal-title":"Vaccine"},{"issue":"2 Suppl.","key":"10.1016\/j.vaccine.2019.04.020_b0035","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.jadohealth.2016.03.041","article-title":"Deciphering the burden of meningococcal disease: conventional and under-recognized elements","volume":"59","author":"Martinon-Torres","year":"2016","journal-title":"J Adolesc Health"},{"issue":"11","key":"10.1016\/j.vaccine.2019.04.020_b0040","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/S1473-3099(15)00217-0","article-title":"Global incidence of serogroup B invasive meningococcal disease: a systematic review","volume":"15","author":"Sridhar","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2019.04.020_b0045","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1586\/eri.13.42","article-title":"The burden and impact of severe and long-term sequelae of meningococcal disease","volume":"11","author":"Vyse","year":"2013","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"1","key":"10.1016\/j.vaccine.2019.04.020_b0050","doi-asserted-by":"crossref","first-page":"162","DOI":"10.4161\/hv.22302","article-title":"The changing epidemiology of meningococcal disease in North America 1945\u20132010","volume":"9","author":"Baccarini","year":"2013","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"10.1016\/j.vaccine.2019.04.020_b0055","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/jpids\/piv065","article-title":"The health burden of invasive meningococcal disease: a systematic review","volume":"5","author":"Strifler","year":"2016","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"10","key":"10.1016\/j.vaccine.2019.04.020_b0060","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s40273-018-0679-5","article-title":"Costs of invasive meningococcal disease: a global systematic review","volume":"36","author":"Wang","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.vaccine.2019.04.020_b0065","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"issue":"15","key":"10.1016\/j.vaccine.2019.04.020_b0070","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2019.04.020_b0075","series-title":"Joanna Briggs institute reviewers' manual: 2016 edition","author":"The Joanna Briggs Institute","year":"2016"},{"issue":"44","key":"10.1016\/j.vaccine.2019.04.020_b0080","article-title":"Metan-an alternative meta-analysis command","volume":"8","author":"Bradburn","year":"1999","journal-title":"Stata Techn Bull"},{"issue":"12","key":"10.1016\/j.vaccine.2019.04.020_b0085","doi-asserted-by":"crossref","first-page":"238","DOI":"10.2807\/esm.10.12.00587-en","article-title":"Epidemiology of invasive meningococcal disease in France in 2003","volume":"10","author":"Perrocheau","year":"2005","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2019.04.020_b0090","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g2301","article-title":"Chronic hypertension and pregnancy outcomes: systematic review and meta-analysis","volume":"348","author":"Bramham","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2019.04.020_b0095","series-title":"General aspects of fitting regression models. Regression modelling strategies","author":"Harrell","year":"2001"},{"issue":"1","key":"10.1016\/j.vaccine.2019.04.020_b0100","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10875-014-0104-6","article-title":"Relationships between Clinico-epidemiological patterns of invasive meningococcal infections and complement deficiencies in French south pacific islands (New Caledonia)","volume":"35","author":"Daures","year":"2015","journal-title":"J Clin Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2019.04.020_b0105","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s15010-013-0439-6","article-title":"Dynamics of childhood invasive meningococcal disease in Israel during a 22-year period (1989\u20132010)","volume":"41","author":"Ben-Shimol","year":"2013","journal-title":"Infection"},{"issue":"5","key":"10.1016\/j.vaccine.2019.04.020_b0110","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jiph.2015.01.009","article-title":"Trends and variations in the epidemiology of meningococcal disease in Kuwait 1987\u20132013","volume":"8","author":"Husain","year":"2015","journal-title":"J Infect Public Health"},{"issue":"37","key":"10.1016\/j.vaccine.2019.04.020_b0115","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES2013.18.37.20581","article-title":"Laboratory-confirmed invasive meningococcal disease: effect of the Hajj vaccination policy, Saudi Arabia, 1995 to 2011","volume":"18","author":"Memish","year":"2013","journal-title":"Euro Surveill"},{"issue":"10","key":"10.1016\/j.vaccine.2019.04.020_b0120","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s10096-008-0535-1","article-title":"Pre-admission clinical course of meningococcal disease and opportunities for the earlier start of appropriate intervention: a prospective epidemiological study on 752 patients in the Netherlands, 2003\u20132005","volume":"27","author":"de Greeff","year":"2008","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2019.04.020_b0125","doi-asserted-by":"crossref","first-page":"e473","DOI":"10.1016\/S2468-2667(17)30157-3","article-title":"Temporal associations between national outbreaks of meningococcal serogroup W and C disease in the Netherlands and England: an observational cohort study","volume":"2","author":"Knol","year":"2017","journal-title":"Lancet Public Health"},{"issue":"24","key":"10.1016\/j.vaccine.2019.04.020_b0130","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1016\/j.vaccine.2012.03.011","article-title":"Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines","volume":"30","author":"Ladhani","year":"2012","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2019.04.020_b0135","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3201\/eid1801.110901","article-title":"Invasive meningococcal capsular group Y disease, England and Wales, 2007\u20132009","volume":"18","author":"Ladhani","year":"2012","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2019.04.020_b0140","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jinf.2008.10.009","article-title":"Hospital admissions for meningococcal infection in Spain (1997\u20132005)","volume":"58","author":"Montero","year":"2009","journal-title":"J Infect"},{"issue":"11","key":"10.1016\/j.vaccine.2019.04.020_b0145","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1023\/A:1010865315425","article-title":"Epidemiology and prognostic factors in meningococcal disease in a small island population: Malta 1994\u20131998","volume":"16","author":"Piscopo","year":"2000","journal-title":"Eur J Epidemiol"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2019.04.020_b0150","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s00508-011-0058-0","article-title":"Epidemiology of invasive meningococcal disease in Austria 2010","volume":"123","author":"Steindl","year":"2011","journal-title":"Wien Klin Wochenschr"},{"issue":"3","key":"10.1016\/j.vaccine.2019.04.020_b0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009662","article-title":"Long-term mortality in patients diagnosed with meningococcal disease: a Danish nationwide cohort study","volume":"5","author":"Roed","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.04.020_b0160","unstructured":"McDonald EJF, Reyholds A, Denham B, Smith-Palmer A, Edwards G, Cameron, C. The epidemiology of invasive meningococcal disease serogroup B in Scotland, 1999\u20132013. ESPID. Dublin, Ireland; 2014 (abstr)."},{"issue":"9","key":"10.1016\/j.vaccine.2019.04.020_b0165","doi-asserted-by":"crossref","first-page":"382","DOI":"10.5694\/mja16.01340","article-title":"Epidemiology of invasive meningococcal B disease in Australia, 1999\u20132015: priority populations for vaccination","volume":"207","author":"Archer","year":"2017","journal-title":"Med J Aust"},{"issue":"5","key":"10.1016\/j.vaccine.2019.04.020_b0170","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1046\/j.1440-1754.2001.00722.x","article-title":"A 10-year serogroup B meningococcal disease epidemic in New Zealand: descriptive epidemiology, 1991\u20132000","volume":"37","author":"Baker","year":"2001","journal-title":"J Paediatr Child Health"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2019.04.020_b0175","first-page":"S41","article-title":"Vaccine preventable diseases and vaccination coverage in Australia, 2001 to 2002","volume":"28","author":"Brotherton","year":"2004","journal-title":"Commun Dis Intell Q Rep"},{"key":"10.1016\/j.vaccine.2019.04.020_b0180","first-page":"S1","article-title":"Vaccine preventable diseases and vaccination coverage in Australia, 2003 to 2005","volume":"31","author":"Brotherton","year":"2007","journal-title":"Commun Dis Intell Q Rep"},{"key":"10.1016\/j.vaccine.2019.04.020_b0185","first-page":"S1","article-title":"Vaccine preventable diseases in Australia, 2005 to 2007","volume":"34","author":"Chiu","year":"2010","journal-title":"Commun Dis Intell Q Rep"},{"issue":"1","key":"10.1016\/j.vaccine.2019.04.020_b0190","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0924-8579(00)00309-5","article-title":"Meningococcal disease in Slovenia (1993-1999): serogroups and susceptibility to antibiotics. Slovenian Meningitis Study Group","volume":"17","author":"Cizman","year":"2001","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"10.1016\/j.vaccine.2019.04.020_b0195","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1086\/596707","article-title":"Severity of meningococcal disease associated with genomic bacterial load","volume":"48","author":"Darton","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2019.04.020_b0200","first-page":"213","article-title":"Estimating the burden of serogroup C meningococcal disease in England and Wales","volume":"5","author":"Davison","year":"2002","journal-title":"Commun Dis Public Health"},{"issue":"Suppl.","key":"10.1016\/j.vaccine.2019.04.020_b0205","first-page":"S1","article-title":"Summary of national surveillance data on vaccine preventable diseases in Australia, 2008\u20132011","volume":"40","author":"Dey","year":"2016","journal-title":"Commun Dis Intell Q Rep"},{"issue":"34","key":"10.1016\/j.vaccine.2019.04.020_b0210","doi-asserted-by":"crossref","first-page":"5765","DOI":"10.1016\/j.vaccine.2011.05.089","article-title":"The burden of hospitalizations for meningococcal infection in Spain (1997\u20132008)","volume":"29","author":"Gil-Prieto","year":"2011","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2019.04.020_b0215","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/pubmed\/fdt004","article-title":"Mortality from meningococcal disease by day of the week: English national linked database study","volume":"35","author":"Goldacre","year":"2013","journal-title":"J Public Health (Oxf)"},{"issue":"7","key":"10.1016\/j.vaccine.2019.04.020_b0220","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.3201\/eid1207.051624","article-title":"Neisseria meningitidis sequence type and risk for death","volume":"12","author":"Gottfredsson","year":"2006","journal-title":"Iceland. Emerg Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2019.04.020_b0225","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1093\/cid\/cir500","article-title":"Comparative long-term adverse effects elicited by invasive group B and C meningococcal infections","volume":"53","author":"Gottfredsson","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"Pt 7","key":"10.1016\/j.vaccine.2019.04.020_b0230","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1099\/jmm.0.46288-0","article-title":"Epidemiology of meningococcal disease in England and Wales 1993\/94 to 2003\/04: contribution and experiences of the Meningococcal Reference Unit","volume":"55","author":"Gray","year":"2006","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.vaccine.2019.04.020_b0235","doi-asserted-by":"crossref","unstructured":"Hanquet GC, Agnew E, Trotter, et al. A quadrivalent vaccine against serogroup B meningococcal disease: a cost-effectiveness study. Health Technology Assessment (HTA); 2014. KCE Reports 231.","DOI":"10.57598\/R231C"},{"issue":"11","key":"10.1016\/j.vaccine.2019.04.020_b0240","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1017\/S0950268809002428","article-title":"Morbidity, mortality and spatial distribution of meningococcal disease, 1974\u20132007","volume":"137","author":"Howitz","year":"2009","journal-title":"Epidemiol Infect"},{"issue":"16","key":"10.1016\/j.vaccine.2019.04.020_b0245","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2018.23.16.18-00158","article-title":"Implementation of MenACWY vaccination because of ongoing increase in serogroup W invasive meningococcal disease, the Netherlands, 2018","volume":"23","author":"Knol","year":"2018","journal-title":"Euro Surveill"},{"issue":"4","key":"10.1016\/j.vaccine.2019.04.020_b0250","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/cid\/ciu881","article-title":"Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales","volume":"60","author":"Ladhani","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"Suppl.","key":"10.1016\/j.vaccine.2019.04.020_b0255","first-page":"32","article-title":"Vaccine preventable diseases and vaccination coverage in Australia, 1999 to 2000","volume":"2002","author":"McIntyre","year":"2002","journal-title":"Commun Dis Intell Q Rep"},{"issue":"Pt 11","key":"10.1016\/j.vaccine.2019.04.020_b0260","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1099\/jmm.0.011312-0","article-title":"Invasive meningococcal disease in Malta: an epidemiological overview, 1994\u20132007","volume":"58","author":"Muscat","year":"2009","journal-title":"J Med Microbiol"},{"issue":"6","key":"10.1016\/j.vaccine.2019.04.020_b0265","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jinf.2017.02.011","article-title":"Characteristics and changes in invasive meningococcal disease epidemiology in France, 2006\u20132015","volume":"74","author":"Parent du Chatelet","year":"2017","journal-title":"J Infect"},{"issue":"26","key":"10.1016\/j.vaccine.2019.04.020_b0270","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1016\/j.vaccine.2018.02.038","article-title":"Epidemiology, clinical presentation, risk factors, intensive care admission and outcomes of invasive meningococcal disease in England, 2010\u20132015","volume":"36","author":"Parikh","year":"2018","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2019.04.020_b0275","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s10096-004-1159-8","article-title":"Epidemiology of meningococcal disease in Switzerland, 1999\u20132002","volume":"23","author":"Ruedin","year":"2004","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2019.04.020_b0280","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1093\/cid\/civ028","article-title":"Outcomes of invasive meningococcal disease in adults and children in Canada between 2002 and 2011: a prospective cohort study","volume":"60","author":"Sadarangani","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2019.04.020_b0285","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1017\/S0950268806007151","article-title":"Capture-recapture analysis to estimate the incidence of invasive meningococcal disease in Germany, 2003","volume":"135","author":"Schrauder","year":"2007","journal-title":"Epidemiol Infect"},{"issue":"3","key":"10.1016\/j.vaccine.2019.04.020_b0290","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1017\/S0950268802007549","article-title":"National enhanced surveillance of meningococcal disease in England, Wales and Northern Ireland, January 1999-June 2001","volume":"129","author":"Shigematsu","year":"2002","journal-title":"Epidemiol Infect"},{"issue":"8","key":"10.1016\/j.vaccine.2019.04.020_b0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071943","article-title":"A decade of invasive meningococcal disease surveillance in Poland","volume":"8","author":"Skoczynska","year":"2013","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.vaccine.2019.04.020_b0300","first-page":"17","article-title":"Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 1999, through 31 December, 2001","volume":"30","author":"Squires","year":"2004","journal-title":"Can Commun Dis Rep"},{"issue":"21","key":"10.1016\/j.vaccine.2019.04.020_b0305","first-page":"177","article-title":"Invasive meningococcal disease in Canada, 1 January 1997 to 31 December 1998","volume":"26","author":"Squires","year":"2000","journal-title":"Can Commun Dis Rep"},{"issue":"8","key":"10.1016\/j.vaccine.2019.04.020_b0310","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/cid\/civ506","article-title":"Disease burden of invasive meningococcal disease in the Netherlands between June 1999 and June 2011: a subjective role for serogroup and clonal complex","volume":"61","author":"Stoof","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.04.020_b0315","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ijid.2016.04.007","article-title":"Meningococcal disease during the Hajj and Umrah mass gatherings","volume":"47","author":"Yezli","year":"2016","journal-title":"Int J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2019.04.020_b0320","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1128\/CMR.19.1.142-164.2006","article-title":"Prospects for vaccine prevention of meningococcal infection","volume":"19","author":"Harrison","year":"2006","journal-title":"Clin Microbiol Rev"},{"issue":"10","key":"10.1016\/j.vaccine.2019.04.020_b0325","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1099\/0022-1317-51-10-855","article-title":"Fatal outcome from meningococcal disease\u2013an association with meningococcal phenotype but not with reduced susceptibility to benzylpenicillin","volume":"51","author":"Trotter","year":"2002","journal-title":"J Med Microbiol."},{"issue":"9306","key":"10.1016\/j.vaccine.2019.04.020_b0330","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0140-6736(02)07716-4","article-title":"W135 meningococcal disease in England and Wales associated with Hajj 2000 and 2001","volume":"359","author":"Hahn\u00e9","year":"2002","journal-title":"Lancet."},{"issue":"5","key":"10.1016\/j.vaccine.2019.04.020_b0335","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jama.1995.03520290042027","article-title":"The changing epidemiology of invasive meningococcal disease in Canada, 1985 through 1992. Emergence of a virulent clone of Neisseria meningitidis","volume":"273","author":"Whalen","year":"1995","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.vaccine.2019.04.020_b0340","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1086\/340414","article-title":"Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electophoretic type-37 complex","volume":"185","author":"Mayer","year":"2002","journal-title":"J Infect Dis."},{"issue":"7570","key":"10.1016\/j.vaccine.2019.04.020_b0345","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/bmj.38968.683958.AE","article-title":"Meningococcal disease and its management in children","volume":"333","author":"Hart","year":"2006","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.vaccine.2019.04.020_b0350","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1086\/649209","article-title":"Changes in Neisseria meningitidis disease epidemiology in the United States, 1998\u20132007: implications for prevention of meningococcal disease","volume":"50","author":"Cohn","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2019.04.020_b0355","first-page":"4","article-title":"Invasive meningococcal disease in elderly people, New South Wales, Australia, 1993 to 2012","volume":"4","author":"Gunaratnam","year":"2013","journal-title":"Western Pac Surveill Response J"},{"issue":"2","key":"10.1016\/j.vaccine.2019.04.020_b0360","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1586\/eri.12.161","article-title":"Genetic susceptibility to meningococcal infection","volume":"11","author":"Dale","year":"2013","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"8","key":"10.1016\/j.vaccine.2019.04.020_b0365","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/sj.gene.6364020","article-title":"Genomic polymorphic profiles in an Irish population with meningococcaemia: is it possible to predict severity and outcome of disease?","volume":"4","author":"Balding","year":"2003","journal-title":"Genes Immun"},{"issue":"7415","key":"10.1016\/j.vaccine.2019.04.020_b0370","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1136\/bmj.327.7415.596","article-title":"Case fatality rates for meningococcal disease in an English population, 1963\u201398: database study","volume":"327","author":"Goldacre","year":"2003","journal-title":"BMJ"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19304712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19304712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:31:13Z","timestamp":1759401073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19304712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":74,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0264410X19304712"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.020","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Case fatality rates of invasive meningococcal disease by serogroup and age: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}